Senhwa Biosciences adds to Series B

Senhwa Biosciences has raised an additional $17 million in a Series B financing to drive its anticancer agents through critical clinical trials. The Taiwan and San Diego, CA based company closed the round with participation from existing and new investors including H&Q Asia Pacific, Morningside and China Investment & Development Co.

North AmericaUSBriefs